BioSenic Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Other Revenue	2.87	0.54	0.27	0.31
Revenue	2.87	0.54	0.27	0.31
Revenue Growth (YoY)	644.04%	104.14%	-14.74%	-
Gross Profit	2.87	0.54	0.27	0.31
Selling, General & Admin	3.37	3.65	1.55	0.57
Research & Development	3.11	3.93	1.03	0.62
Operating Expenses	6.48	7.58	2.58	1.19
Operating Income	-3.61	-7.04	-2.32	-0.88
Interest Expense	-5.61	-5.95	-0.74	-0.11
Interest & Investment Income	0.05	0.06	0	-
Currency Exchange Gain (Loss)	-	-	0	-
Other Non Operating Income (Expenses)	1.54	-	0.01	-
EBT Excluding Unusual Items	-7.62	-12.93	-3.05	-0.98
Asset Writedown	-1.8	-16.09	-	-
Pretax Income	-7.62	-29.03	-3.05	-0.98
Income Tax Expense	-0.03	-0.01	-	-
Earnings From Continuing Operations	-7.59	-29.02	-3.05	-0.98
Minority Interest in Earnings	0.15	0.24	-	-
Net Income	-7.44	-28.78	-3.05	-0.98
Net Income to Common	-7.44	-28.78	-3.05	-0.98
Shares Outstanding (Basic)	173	137	152	0
Shares Outstanding (Diluted)	173	137	152	0
Shares Change (YoY)	-5.94%	-10.11%	230591.24%	-
EPS (Basic)	-0.04	-0.21	-0.02	-14.89
EPS (Diluted)	-0.04	-0.21	-0.02	-14.89
Free Cash Flow	-2.36	-3.47	-1.92	-1.07
Free Cash Flow Per Share	-0.01	-0.03	-0.01	-16.15
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-125.52%	-1296.32%	-871.43%	-281.09%
Profit Margin	-259.05%	-5299.82%	-1146.24%	-315.38%
Free Cash Flow Margin	-82.24%	-639.04%	-719.93%	-341.99%
EBITDA	-3.36	-6.8	-2.26	-0.86
EBITDA Margin	-116.89%	-	-	-276.92%
D&A For EBITDA	0.25	0.24	0.06	0.01
EBIT	-3.61	-7.04	-2.32	-0.88
EBIT Margin	-125.52%	-	-	-281.09%
Revenue as Reported	2.87	0.54	0.27	0.31

Updated Sep 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.